Anti-GM1 ganglioside antibodies in Parkinson's disease

Acta Neurol Scand. 2002 Jul;106(1):54-7. doi: 10.1034/j.1600-0404.2002.01240.x.

Abstract

Objectives: To determine whether anti-GM1 antibodies are increased in Parkinson's disease (PD).

Methods: Serum immunoglobulin M (IgM) and IgG anti-GM1 antibodies were detected by enzyme-linked immunosorbent assay (ELISA) in 147 patients with PD and in 186 age-matched normal control subjects. Sera were assayed at initial dilution of 1:800 for IgM and 1:200 for IgG and were considered positive at absorbance values exceeding the value of 0.05 for IgM and 0.1 for IgG.

Results: Forty patients with PD (27.2%) had sera positive for IgM anti-GM1 antibodies, whereas only five normal controls (2.7%) resulted positive (P < 0.0001). Most of patients (75%) with positive sera had a tremor-dominant form of PD. Only two patients with PD (1.4%) and none of normal controls had sera positive for IgG anti-GM1 antibodies.

Conclusion: A consistent portion of parkinsonians, mainly with a tremor-dominant form of PD, may have increased circulating IgM anti-GM1 antibodies.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Autoantibodies / blood*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • G(M1) Ganglioside / immunology*
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Male
  • Middle Aged
  • Parkinson Disease / blood*
  • Parkinson Disease / complications
  • Parkinson Disease / immunology*
  • Reference Values
  • Serologic Tests
  • Tremor / etiology

Substances

  • Autoantibodies
  • Immunoglobulin G
  • Immunoglobulin M
  • G(M1) Ganglioside